Evogene (EVGN) Tops Q2 EPS by 19c

Evogene (NASDAQ: EVGN) reported Q2 EPS of ($1.06), $0.19 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $914 thousand versus the consensus estimate of $775 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Texas Capital Securities Reiterates Buy Rating on Texas Pacific Land Trust (TPL)
• Cushman & Wakefield names two capital markets leaders in APAC